AbbVie (ABBV) Financial Analysis & Valuation | Quarter Chart
AbbVie (ABBV)
ABBVPrice: $212.99
Fair Value: 🔒
🔒score
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor f... more
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The compa... more
Description
Shares
| Market Cap | $376.31B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Michael |
| IPO Date | 2013-01-02 | CAGR | 0.1% |
| Employees | 55,000 | Website | www.abbvie.com |
| Div. Yield | 3.09% | Payout Ratio | 3.25% |
| Buy Back Yield | 0.38% | Total Yield | 3.47% |
ABBV chart loading...
Fundamentals
Technicals
| Enterprise Value | $444.48B | P/E Ratio | 103.9 |
| Forward P/E | 13.12 | PEG Ratio | -2.25 |
| P/S Ratio | 6.11 | P/B Ratio | 14.02 |
| P/CF Ratio | 18.19 | P/FCF Ratio | 18.42 |
| EPS | $2.05 | EPS Growth 1Y | -13.29% |
| EPS Growth 3Y | -52.02% | EPS Growth 5Y | -28.23% |
| Revenue Growth 1Y | 9.5% | Gross Margin | 0.71% |
| Operating Margin | 0.28% | Profit Margin | 0.06% |
| ROE | 0.68% | ROA | 0.03% |
| ROCE | 0.18% | Current Ratio | 0.8 |
| Quick Ratio | 0.68 | Cash Ratio | 0.22 |
| Debt/Equity | 2.65 | Interest Coverage | 5.96 |
| Altman Z Score | 2.49 | Piotroski Score | 7 |